Dr. Peter Mitchell Kally, MD

Dr. Kally practices at Virginia Mason Medical Center - HOPD in Seattle, Washington.

Dr. Kally's NPI, 1730534801, was assigned on April 26, 2016. Dr. Kally holds Washington license MD61263154.

Dr. Kally's primary practice is Virginia Mason Medical Center - HOPD, at 1100 9th Ave, Seattle, WA 98101.

Dr. Kally's primary practice is Virginia Mason Medical Center - HOPD in Seattle, Washington. Dr. Kally is also affiliated with Virginia Mason Medical Center. The medical group on file is Virginia Mason Medical Center. Dmand AI also links Dr. Kally to 1 more group practice or clinic and 1 imaging center, each named with a free account. Dr. Kally's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kally practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Kally's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Kally is licensed in Washington.

CMS data shows 1,146 Medicare services from Dr. Kally across 15 procedure codes in 2024, for 404 Medicare patients. Medicare paid $111,638 for them.

CMS counts 404 Medicare patients who saw Dr. Kally in 2024. The largest group is 75 to 84, with 172 patients. 64% of them have high cholesterol, and 61% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.00, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kally's median patient age at 74, with 64% women.

In 2024, Dr. Kally wrote 296 Medicare Part D claims for 179 patients. 95% of them were for generic drugs. CMS names the drug for 222 of them, across 5 drugs with 11 or more claims each, at $1,739 in total drug cost. In 2023, CMS named 272 claims across 6 drugs.

Dr. Kally accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kally as offering telehealth. CMS counts 13 procedures of melanoma (skin cancer) excision by Dr. Kally, more than 67% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Kally, published from 2012 to 2024. 2022 was the busiest year, with 3. Dr. Kally has published most often in Ophthalmic Plast Reconstr Surg. Dr. Kally's most frequent co-authors are Alon Kahana, MD, Amro Omari, MD and Thai H. Do, MD.

CMS Open Payments shows 99 general payments to Dr. Kally from 16 drug and device companies from 2020 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Amgen Inc. paid the most, $20,749.